Innovative Science

There is an urgent need for therapies to treat or prevent devastating viral diseases in immunocompromised patients with T cell deficiencies who have limited or no treatment options.
‍
We develop allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidates designed to treat or prevent life-threatening viral diseases.

Step 1: Proprietary VST Profiling and Antigen Selection Process

‍

Step 2: Rapid and Scalable Off-the-Shelf VST Manufacturing

One manufacturing run from a single donor can generate hundreds of doses of VSTs.

Step 3: Cytomatch™ and Immediate Access to Our Allogeneic VST Therapies

‍

AlloVir’s Proprietary, Highly Efficient and Industrialized Platform Provides Key Advantages

The Heroic Role of T Cells Fighting Viral Infections

In healthy individuals, T cells from the body’s natural defense system provide protection against devastating viruses. For patients with T cell deficiencies, viruses may be uncontrolled, leading to potentially devastating and life-threatening consequences.

Developing An Immune System Outside the Body

T cells from healthy patients with the right characteristics are activated, expanded, and preserved for use on patients in need.

We Treat High-Risk Individuals

Our allogeneic, off-the-shelf VST therapy candidates benefit patients with T cell deficiencies including transplant recipients, immunocompromised cancer patients, the elderly, and the very young at a higher risk of the devastating consequences of viral disease.

BK Virus
Cytomegalovirus
Adenovirus
Epstein-Bar Virus

Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus

Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Human Herpesvirus-8

Bladder

Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy

Brain

Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy

Kidneys

Nephritis
Acute/chronic renal failure
End stage renal disease

Lungs

Pneumonia
Bronchitis
Respiratory failure

Eyes

Retinitis
Blindness

Liver

Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma

Small/Large Intestine

Colitis
Ulceration / perforation
Intestinal bleeding

Malignancy

Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.

view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.

learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.

meet